findmyKOL
Clinical trialNCT02135874CompletedPhase 2Interventional

Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia

SponsorM.D. Anderson Cancer CenterEnrollment16Acute Bilineal LeukemiaAcute Biphenotypic LeukemiaAcute Leukemia of Ambiguous LineageAcute Undifferentiated LeukemiaMixed Phenotype Acute LeukemiaMixed Phenotype Acute Leukemia, B/Myeloid, Not Otherwise Specified+2 more conditions
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • M D Anderson Cancer Center

    Houston, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
27 Oct 2014
Primary completion
21 Feb 2023
Completion
21 Feb 2023
Last update posted
22 Mar 2024
Registered enrollment
16
Registry id
NCT02135874

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.